Eleven-Year Follow-up of Idiotype Vaccine and DA-EPOCH-Rituximab in Untreated Mantle Cell Lymphoma: Correlation of Survival with Idiotype Immune Response

被引：4
|
作者：
Grant, Cliona
Neelapu, Sattva S. [2 ,3 ]
Kwak, Larry W.
Dunleavy, Kieron
White, Therese
Miller, Barry W.
Jaffe, Elaine S. [1 ]
Steinberg, Seth M. [4 ]
Bird, Brian Healey [5 ]
Wilson, Wyndham H. [6 ]
机构：
[1] NCI, Ctr Canc Res, Pathol Lab, Bethesda, MD 20892 USA
[2] UT MD Anderson Canc Ctr, Div Canc Med, Houston, TX USA
[3] UT MD Anderson Canc Ctr, Ctr Canc Immunol Res, Houston, TX USA
[4] NCI, Biostat & Data Management Sect, NIH, Rockville, MD USA
[5] Bons Secours Hosptial, Cork, Ireland
[6] NCI, Metab Branch, NIH, Bethesda, MD 20892 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.2707.2707
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1164 / 1165
页数：2
相关论文
共 29 条
  • [1] Idiotype vaccine following EPOCH-rituximab treatment in untreated mantle cell lymphoma.
    Wilson, WH
    Neelapu, S
    White, T
    Hegde, U
    Pittaluga, S
    Hakim, F
    Stetler-Stevenson, M
    Frye, R
    Steinberg, S
    Jaffe, ES
    Gress, R
    Staudt, L
    Janik, J
    Kwak, L
    BLOOD, 2002, 100 (11) : 162A - 162A
  • [2] Idiotype vaccine and dose-adjusted EPOCH-rituximab treatment untreated mantle cell lymphoma: Preliminary report on clinical outcome and analysis of immune response.
    Wilson, WH
    Neelapu, S
    Rosenwald, A
    White, T
    Dunleavy, K
    Pittaluga, S
    Hakim, F
    Stetler-Stevenson, M
    Steinberg, S
    Jaffe, ES
    Gress, R
    Wright, G
    Staudt, L
    Janik, J
    Kwak, L
    BLOOD, 2003, 102 (11) : 105A - 106A
  • [3] Bortezomib plus DA-EPOCH-rituximab followed by bortezomib maintenance versus observation in previously untreated mantle cell lymphoma (MCL)
    Grant, C.
    Dunleavy, K.
    Tweito, M.
    Steinberg, S. M.
    Pittaluga, S.
    Jaffe, E. S.
    Wiestner, A.
    Wilson, W. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Association of idiotype vaccine-induced T-cell response with improved survival and time-to-next treatment (TTNT) in untreated mantle cell lymphoma (MCL).
    Dunleavy, Kieron
    Neelapu, Sattva Swarup
    Kwak, Larry W.
    Grant, Cliona
    Santos, Carlos F.
    Popa, Mihaela A.
    White, Therese
    Miller, Barry
    Jaffe, Elaine S.
    Steinberg, Seth M.
    Wilson, Wyndham Hopkins
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Quantitative Baseline Circulating Tumor DNA Levels Correlate with GM-CSF Response to Idiotype Vaccine in Untreated Mantle Cell Lymphoma
    Roschewski, Mark
    Dunleavy, Kieron
    Neelapu, Sattva S.
    Pittaluga, Stefania
    Melani, Christopher Joseph
    Jaffe, Elaine S.
    Shovlin, Margaret
    Crossley, Beryl
    Kong, Katie
    Jacob, Allison
    Kwak, Larry
    Wilson, Wyndham H.
    BLOOD, 2016, 128 (22)
  • [6] Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma
    Yamshon, Samuel
    Chen, Gui Zhen
    Gribbin, Caitlin
    Christos, Paul
    Shah, Bijal
    Schuster, Stephen J.
    Smith, Sonali M.
    Svoboda, Jakub
    Furman, Richard R.
    Leonard, John P.
    Martin, Peter
    Ruan, Jia
    BLOOD ADVANCES, 2023, 7 (21) : 6579 - 6588
  • [7] Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma
    Ruan, Jia
    Martin, Peter
    Christos, Paul
    Cerchietti, Leandro
    Tam, Wayne
    Shah, Bijal
    Schuster, Stephen J.
    Rodriguez, Amelyn
    Hyman, David
    CaIvo-Vidal, Maria Nieves
    Smith, Sonali M.
    Svoboda, Jakub
    Furman, Richard R.
    Coleman, Morton
    Leonard, John P.
    BLOOD, 2018, 132 (19) : 2016 - 2025
  • [8] Ten-year follow-up of pentostatin combined with cyclophosphamide, and rituximab in previously untreated indolent B-cell lymphoma.
    Khashab, Tamer
    Niaz, Muhammad Obaid
    Hagemeister, Fredrick B.
    Romaguera, Jorge Enrique
    Fanale, Michelle A.
    Pro, Barbara
    McLaughlin, Peter
    Rodriguez, Maria Alma
    Neelapu, Sattva Swarup
    Fayad, Luis
    Younes, Anas
    Feng, Lei
    Berkova, Zuzana
    Jain, Neeraj
    Sehgal, Lalit
    Vega, Francisco
    Kwak, Larry W.
    Samaniego, Felipe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group
    Purroy, Noelia
    Bergua, Juan
    Gallur, Laura
    Prieto, Julio
    Lopez, Luis A.
    Sancho, Juan M.
    Garcia-Marco, Jose A.
    Castellvi, Josep
    Montes-Moreno, Santiago
    Batlle, Ana
    Gonzalez de Villambrosia, Sonia
    Carnicero, Fernando
    Ferrando-Lamana, Lucia
    Piris, Miguel A.
    Lopez, Andres
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (02) : 188 - 198
  • [10] Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
    Romaguera, Jorge E.
    Fayad, Luis E.
    Feng, Lei
    Hartig, Kimberly
    Weaver, Pamela
    Rodriguez, Maria Alma
    Hagemeister, Fredrick B.
    Pro, Barbara
    McLaughlin, Peter
    Younes, Anas
    Samaniego, Felipe
    Goy, Andre
    Cabanillas, Fernando
    Kantarjian, Hagop
    Kwak, Larry
    Wang, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (02) : 200 - 208
123